Unnecessary medical spending doesn’t decrease with high-deductible plans

High-deductible health plans have been framed as a way to give healthcare consumers more “skin in the game,” leading them to avoid low-value services as a way to save money. According to researchers from the USC Schaeffer Center for Health Policy and Economics and the RAND Corporation, they’re having little to no impact.

The study, published in the American Journal of Managed Care, examined insurance claims data from more than 376,000 patients aged between 18 and 63, comparing spending before and after they switched to a high-deductible plan on services deemed to have unclear or no clinical benefit by healthcare groups. The 26 low-value services ranged from imaging for nonspecific low back pain to preoperative chest radiography to undergoing an MRI for an uncomplicated headache.

“Theoretically, the increased cost-burden of those plans could be an incentive for consumers to pinch pennies by specifically avoiding low-value services that don’t offer them clear clinical benefits,” said Rachel Reid, MD, MS, a Schaeffer Center fellow, associate physician policy researcher at RAND, primary care physician at Brigham and Women’s Hospital and one of the study’s authors. “Instead, we found that patients are reducing their spending overall, but not for low-value services in particular.”

Overall, those in these higher-deductible plans did reduce their annual spending on outpatient procedures by $231.60 compared to customers on traditional health plans, including spending $22.17 less on imaging services and a decrease in laboratory services. For the low-value services, however, the difference between the high-deductible and traditional health plan patients was only $3.

Reid and her coauthors said this matched other research into consumer behavior on high-deductible plans—spending is reduced, but on all services, low-value or not. With fewer customers understanding their health benefits, they don’t shop based on price as expected and may avoid high-value services and preventive care out of concern over paying their medical bills as out-of-pocket spending continues to climb.

The study offered two possible solutions: focusing on value-based insurance design, which can vary cost-sharing based on a value of a service and payment arrangements which focus on providers, not patients, having “skin in the game” and encourage physicians to steer patients away from low-value services.

“Use of low-value services appears to vary substantially among provider organizations,” Reid and her coauthors wrote. “This suggests that providers can influence demand for value-conscious care and that appropriately targeted provider incentives have potential to reduce wasteful low-value spending. More research is needed to understand how provider and group characteristics influence delivery of low-value services.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.